Reducing ventilator-associated pneumonia in neonatal intensive care unit using “VAP prevention Bundle†: a cohort study

http://7thspace.com/headlines/514664/reducingventilatorassociatedpneumoniainneonatalintensivecareunitusingvappreventionbundleacohort_study.html http://7thspace.com/headlines/514664/reducing_ventilator_associated_pneumonia_in_neonatal_intensive_care_unit_using_vap_prevention_bundle_a_cohort_study.html

Reducing ventilator-associated pneumonia in neonatal intensive care unit using “VAP prevention Bundle”: a cohort study

Reducing ventilator-associated pneumonia in neonatal intensive care unit using 'VAP prevention Bundle': a cohort study

Ventilator-associated pneumonia (VAP) is a serious health care- associated infection, resulting in high morbidity and mortality. It also prolongs hospital stay and drives up hospital costs.

Measures employed in preventing ventilator- associated pneumonia in developing countries are rarely reported. In this study we tried to assess the efficacy of our designed 'VAP prevention bundle'in reducing VAP rate in our neonatal intensive care unit (NICU).MethodThis prospective before-and-after study was conducted at university hospital NICU, all neonates who had mechanical ventilation for ≥ 48 h were eligible.

VAP rates were evaluated before (phase-I) and after (phase-II) full implementation of comprehensive preventive measures specifically designed by our infection control team.

Results: Of 143 mechanically ventilated neonates, 73 patients developed VAP (51 %) throughout the study period (2500 mechanical ventilation days). The rate of VAP was significantly reduced from 67.8 % (42/62) corresponding to 36.4 VAP episodes/1000 mechanical ventilation days (MV days) in phase-I to 38.2 % (31/81) corresponding to 23 VAP/1000 MV days (RR 0.565, 95 % confidence interval 0.408-0.782, p = 0.0006) after VAP prevention bundle implementation (phase-II).

Parallel significant reduction in MV days/case were documented in post-intervention period (21.50 ± 7.6 days in phase-I versus 10.36 ± 5.2 days in phase-II, p = 0.000). There were a trend toward reduction in NICU length of stay (23.9 ± 10.3 versus 22.8 ± 9.6 days, p = 0.56) and overall mortality (25 % versus 17.3 %, p = 0.215) between the two phases but didn't reach statistical significance.

The commonest micro-organisms isolated throughout the study were gram-negative bacteria (63/66, 95.5Â %) particularly Klebsilla pneumonia (55/66, 83.4Â %).

Conclusion: Implementation of multifaceted infection control bundle resulted in reduction of VAP rate, length of stay in our NICU.

Author: Seham AzabHanan SherbinySafaa SalehWafaa ElsaeedMona ElshafieyAhmed SiamMohamed ArafaAshgan AlghobashyEman BendaryMaha BassetSanaa IsmailNagwa AkeelNahla ElsamadWesam mokhtarTarek Gheith Credits/Source: BMC Infectious Diseases 2015, 15:314

Published on: 2015-08-05

Copyright by the authors listed above - made available via BioMedCentral http://www.biomedcentral.com/info/about/openaccess (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk . If you wish submit your own press release, click here .

Discussions

Robert Simms / Business Manager Novus Medical Inc. mobile +1- 905-407-3005 / office +1-866-926-9977 2333 Wyecroft Rd., Unit 9, Oakville, Ontario, L6L 6L4 Canada

visit novusmedical.ca http://novusmedical.ca/ for more medical innovation.